AGT and type 2 diabetes mellitus: At baseline, most patients had hypertension (80.2%) and 25.6% had type 2 diabetes; 14.0% and 26.7% of patients were receiving concomitant angiotensin-converting enzyme inhibitors and angiotensin II antagonists, respectively, during study treatment (Table 1).